Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2014)
11 slides from Patrys's shareholder meeting presentation, Nov 12, 2014
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Roger McPherson, CEO 12 November 2014 ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Patrys Limited to be materially different
Slide 3: Key Focus Areas
Key Focus Areas o Oncology-focused clinical-stage Company For personal use only o Deep pipeline of novel cancer-specific IgM monoclonal antibodies o PAT-SM6 moving to next clinical trial o Out-licensing program for clinical product PAT- SC1 o CAR T cell program o Diagnostic focus for lead product PA
Slide 4: Experienced & Capable Team
Experienced & Capable Team For personal use only John Read Chairman Mike Stork Non-Executive Director Suzy Jones Non-Executive Director Roger McPherson CEO (Interim), CFO & Company Secretary Frank Hensel VP Research & Development Deanne Greenwood Senior Director Business Development Valentina Dublje
Slide 5: Pipeline
Pipeline For personal use only Product Discovery Preclinical Phase I Phase 2a (Target) Phase I PAT-SM6 Melanoma Completed (GRP78) PAT-SM6 Phase I/IIa Multiple Myeloma Single Agent Completed 2013 (GRP78) PAT-SM6 Phase Ib/IIa Multiple Myeloma Combination Carfilzomib Commence 2015 (GRP78) PAT-LM1 Solid
Slide 6: FY13 Programme Highlights – I
FY13 Programme Highlights – I For personal use only PAT-SM6: Phase I/IIa multi-dose multiple myeloma trial: o Completed Phase I/IIa clinical trial in multiple myeloma in Dec 2013 o Results showed indications of clinical efficacy with 33% of treated patients showing evidence of stable disease (SD) ac
Slide 7: FY13 Programme Highlights – II
FY13 Programme Highlights – II For personal use only PAT-SC1: o Out-licensing program ongoing focused on Japan, China, South Korea and India given the incidence of gastric cancer in these populations PAT-LM1: o Program suspended due to insufficient funds PAT-SM3, PAT-SM4 and PAT-H12: o Target identi
Slide 8: PAT-SM6 & Carfilzomib Trial Timelines
PAT-SM6 & Carfilzomib Trial Timelines For personal use only Manufacturing/Paul Ehrlich Institut (PEI): o Complications in the manufacturing process have resulted in a delay in final PAT-SM6 material being available for the planned combination clinical trial o The manufacturing problems that have occ
Slide 9: PAT-SC1 Out-Licensing Program
PAT-SC1 Out-Licensing Program For personal use only o A number of potential partners are evaluating PAT-SC1 o One potential partner generated excellent in vivo data with PAT-SC1 o PER.C6® license not available in many regions including India and China, therefore potential partners in these regions m
Slide 10: CAR T Cell Program
CAR T Cell Program For personal use only o CAR program underway with European based development company o CAR constructs have been developed for 2 products in Patrys’ pipeline. Cell surface expression has been confirmed and T-cell activation assays are underway o Feasibility studies are being conduc
Slide 11: For Further Information
For personal use only For Further Information Contact Details: Mr. Roger McPherson, Chief Executive Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com